Genespire Appoints Karen Aiach Pignet As Chief Executive Officer
09/12/24, 5:16 AM
Location
milanIndustry
biotechnology
health care
Position
chief executive officer
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer to bolster its position as a leader in in-vivo lentiviral gene therapy. Karen joins as the company progresses lead candidate, GENE202, for the treatment of methylmalonic acidemia (MMA) into clinical development.
Company Info
Location
milan, lombardy, italy
Additional Info
Genespire is a biotechnology company focused on the development of durable and transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners.